ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) FY2026 YTD Q2 P&L / Income Statement

ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) FY2026 YTD Q2 P&L / Income Statement

Income statement for 2026-01-01 through 2026-06-30. View: Revenue categories. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total revenues

235,259,000 US dollars

Cost of sales

20,723,000 US dollars

Gross profit (calculated)

214,536,000 US dollars

Operating expenses (calculated)

207,196,000 US dollars

Income (loss) from operations

7,340,000 US dollars

Total other income (expense)

negative 3,397,000 US dollars

Income (loss) before income taxes

3,943,000 US dollars

Provision for income taxes

229,000 US dollars

Segment and consolidated net income (loss)

3,714,000 US dollars

Product revenue, net

235,259,000 US dollars

Other revenue

0 US dollars

Research and development

50,982,000 US dollars

Selling, general and administrative

156,214,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.